Contact Us
Drug Search Results
More Filters [+]

AZD-4547

Alternative Names: AZD-4547, AZD4547, AZD 4547, ABSK091, ABSK-091, ABSK 091
Latest Update: 2024-12-12
Latest Update Note: Clinical Trial Update

Product Description

an oral FGFR1-3 inhibitor (Sourced from: https://ascopubs.org/doi/10.1200/JCO.19.02630)

Mechanisms of Action: FGFR Antagonist,TK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AZD-4547

Countries in Clinic: China, United Kingdom

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Adenocarcinoma|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Transitional Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ABSK091-203

P2

Recruiting

Transitional Cell Carcinoma

2025-09-30

57%
National Lung Matrix Trial

P2

Active, not recruiting

Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Adenocarcinoma

2024-09-01

CTR20222326

P2

Recruiting

Transitional Cell Carcinoma

None

Recent News Events

Date

Type

Title

04/04/2024

PubMed

 Fibroblast growth factor receptor inhibitors mitigate the neuropathogenicity of Borrelia burgdorferi or its remnants ex vivo.

04/01/2024

PubMed

 Hyperglycemia activates FGFR1 via TLR4/c-Src pathway to induce inflammatory cardiomyopathy in diabetes.

01/30/2024

PubMed

 The Application of Artificial Intelligence and Drug Repositioning for the Identification of Fibroblast Growth Factor Receptor Inhibitors: A Review.

09/12/2023

News Article

 Fibroblast Growth Factor Receptor 2 market research report has seen immense growth at an exponential CAGR rate of 7% from 2023 to 2030 and provides in-depth analysis of Fibroblast Growth Factor Receptor 2 market.

09/05/2023

News Article

 Stay Ahead of the Curve in the Fibroblast Growth Factor Receptor 2 Market by 2030

08/16/2021

News Article

 Outlook on the Fibroblast Growth Factor Receptor Inhibitor Drug Global Market to 2026 - Focus on Belvesra, Pemazyre and Truseltiq

08/13/2021

News Article

 Global Fibroblast Growth Factor Receptor Inhibitor Drug Market to 2026 - Opportunity & Clinical Trials Insights - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions